Vir Biotechnology, Inc. (VIR)

Vir Biotechnology is a mixed-fundamentals clinical-stage biotech with a fortress balance sheet but no recurring profitability. FY2025 revenue was only $68.6M against a $438M net loss, and the sole profitable recent quarter (Q2 2026, +$80.1M) was inflated by a one-time $239.3M Astellas upfront payment for the VIR-5500 prostate-cancer program; the underlying business still burns roughly $130-165M per quarter. The positives are real and disclosed: roughly $1.01B of cash and investments (more than half the market cap), a net-cash position, H1 2026 operating cash outflow of just -$9.1M versus -$198.3M a year earlier, no going-concern warning in the SEC filings, up to $1.39B in future Astellas milestones, ECLIPSE Phase 3 hepatitis-delta topline data due late 2026/early 2027, and a $21.67 analyst consensus target far above the current price. The negatives are equally real: deeply negative TTM margins and returns, revenue down about 50% annualized over five years, roughly 22% share-count dilution, a CFO departure, no insider buying, an Altman Z of 2.91 and Piotroski score of 2, and both discounted-cash-flow models producing negative values (model breakdown typical for a pre-profit biotech). Verdict: watchlist-grade fundamentals with genuine catalysts; the balance sheet is strong but the operating model is still unproven.

Dominant catalyst is the market-rewarded Q2 2026 earnings beat (announced 2026-08-12, partially priced) — a ~40% EPS surprise and swing to quarterly profitability with cash runway into 2028 that is still repricing higher two weeks post-print; the in-window media tape is clearly positive (aggregate polarity ≈ +0.14) and the sentiment delta is determinate but essentially flat-positive versus a mildly positive baseline, with the Red-Flag Screen clean and no cap applied.

VIR is in an intact intermediate uptrend — price 10.44 sits above the rising SMA50 (9.82, up from 9.65 two weeks ago) and well above the SMA200 (8.73), with the MACD line still positive (0.32) — while the stock has pulled back ~13% from the 09-02 high of 11.94 into a support shelf at 10.23–10.38. The pullback has reset momentum from overbought (RSI 71.6 on 09-01) to neutral (50.4) and driven Williams %R to −87.7 (oversold), a textbook dip-buy configuration inside an uptrend. Entry: limit at 10.38 (the 09-11 swing low, below the 10.44 close and just under EMA21 at 10.55). Protective stop: structural swing low 10.23 (09-15 regular-session low, the only sub-entry low in the M=3 window) minus a 0.11 buffer = 10.12, then floored by the pullback ATR rule to 1.0×ATR below entry → 9.84, safely below the support shelf. Targets: 11.46 (2.0×ATR, under the 11.94 high) and 12.27 (3.5×ATR). Risk 0.54 = 1.0×ATR, R/R = 2.00. Volume is ample ($22.1M 20-day dollar volume) and no earnings or dividend event sits inside the 15-trading-day window (confirmed earnings 2026-11-04 is beyond the 2026-10-06 horizon).